Umbilical CB-NK Expressing sIL-15 & PD-L1 +/- Atezolizumab in NSCLC Pts Refractory to PD-1/PD-L1

Open to people ages 18 years and up

• Documented informed consent of the participant
• Agreement to allow the use of archival tissue from diagnostic tumor biopsies
• Age: ≥ 18 years
• ECOG 0 to 1
• NSCLC patients with advanced, metastatic, or recurrent disease, previously treated with a PD-1 or PDL-1 immune checkpoint inhibitor, either as single agent or in combination with chemotherapy or other immunotherapy or experimental agents
• Radiographically demonstrated tumor progression on or after PD-1/PD-L1 immune checkpoint inhibitor treatment
• Preserved organ function and recovery of prior drug related toxicities (except alopecia or grade 2 anemia) to grade 1 or better
• No cytotoxic chemotherapy or immunotherapy over the three weeks prior to lymphodepletion
• Histologically confirmed Non-Small Cell Lung Cancer
• Measurable disease as per RECIST criteria 1.1
• Fully recovered from the acute toxic effects (except alopecia) to ≤ Grade 1 to prior anti- cancer therapy
• Cardiac ejection fraction ≥ 50% and no clinically significant EKG findings (same criteria must also be met for patients selected for a second course of therapy).
• ANC ≥ 1,500/mm³
• Hgb ≥ 8 g/dl
• Platelets ≥ 100,000/mm3
• Total bilirubin ≤ 1.5 X ULN
• AST ≤ 1.5 x ULN
• ALT ≤ 1.5 x ULN
• AP ≤ 1.5 x ULN
• Creatinine within 1.5 times the normal upper limit or with a creatinine clearance of ≥ 50 mL/min per 24-hour urine test or the Cockcroft-Gault formula
• If not receiving anticoagulants: International Normalized Ratio (INR) OR Prothrombin (PT) ≤ 1.5 x ULN. If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants

• Seronegative for HIV Ag/Ab combo, HCV*, active HBV (Surface Antigen Negative)

  *If positive, Hepatitis C RNA quantitation must be performed.

• Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• Agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 06 months after the last dose of protocol therapy.
  • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only).

• Autologous stem cell transplant within 1 year prior to Day 1 of protocol therapy
• Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to Day 1 of protocol therapy
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
• Active diarrhea
• Clinically significant uncontrolled illness
• Active infection requiring antibiotics
• Known history and/or positive serology for immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection
• Diagnosis of Gilbert's disease
• Other active malignancy
• Females only: Pregnant or breastfeeding
• Severe (grade 3 or higher) immune related adverse events during prior PD-1 inhibitor treatment
• Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
• Concomitant use of other investigational agents
• Patients with EGFR mutations or ALK translocations in their tumors, unless treatment with the indicated tyrosine kinase inhibitor has failed
• Active brain metastases. Previously treated brain metastasis must demonstrate stability on subsequent MRI scans.
• Adults lacking capacity to give their informed consent will be excluded from participation
• Cardiac ejection fraction < 50%
• Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).